The City of Hope now seeks patients for a Phase 1 clinical trial centering on an investigational vaccine that uses a person’s own cells, a beta cell protein and vitamin D3 to potentially treat Type 1 Diabetes. Part of the Wanek Family Project for Type 1 Diabetes at City of Hope, the trial is but one of a number of initiatives part of a quest to find a cure for diabetes. A first-of-its-kind trial for Type 1 Diabetes, the approach now unfolds in the United States but was tested in Europe and evidenced positive early results. Known as the PIpepToIDC vaccine, the “inverse” vaccine, which was previously evaluated for safety and feasibility in a clinical trial in the Netherlands, now will be tested for the first time in America.
TrialSite breaks this important update down for the TrialSite Network.
What is the PipepToIDC vaccine study?
The Phase 1 clinical trial (NCT04590872) investigates the side-effects PipepToIDC vaccine in treating patients with Type 1 diabetes who use insulin and don’t have any other diabetes-related health complications.
As Type 1 diabetes is an autoimmune disease, this means that the patient’s immune system, which usually protects against foreign inva...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).